Genetic factors, serum markers, and the risk of TIA and stroke. Collection and storage of peripheral blood samples for neurovascular research in the Rotterdam Stroke Databank

Genetic factors, serum markers, and the risk of TIA and stroke. Collection and storage of peripheral blood samples for neurovascular research in the Rotterdam Stroke Databank - Genetic and serum factors and risk of neurovascular events.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30779

Enrollment

1000

Registered

2007-06-12

Start date

2007-09-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarct / hemorrhage Stroke

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients: 1) Acute stroke treated in the Stroke Unit of the department of Neurology 2) Transient ischemic attack (TIA) or minor ischemic stroke at the outpatient TIA service 3) Patient should be able to give informed consent Control persons: Spouses, partners, friends or neighbours of patients who are included in the current study, without a history of ischemic or hemorrhagic stroke or TIA.

Exclusion criteria

Exclusion criteria: Relatives of patients do not qualify for control persons (because future research will include the study of genetic polymorphisms). Persons who are not able to give informed consent will not be included in the study.

Design outcomes

Primary

Measure	Time frame
The study is primarily aimed at the collection and storage of blood samples and questionnaire data for future scientific research. The exact content of this study is at this moment only partially specified. We aim to answer the following research questions: 1) Are (genetic) factors that play a role in blood coagulation (hemostasis) associated with the risk of TIA or stroke in this clinical cohort? With more specific sub-questions: -are levels of fibrinogen and fibrinogen-degradation products associated with the risk of the outcome-measures under study? - are variations in the fibrinogen-FGA en FGG genes associated with the risk of the outcome-measures under study? -are other genetic variations that play a role in hemostasis associated with the risk of the outcome-measures under study? 2) Are new genetic risk factors for atherosclerosis associated with the risk of TIA or stroke in this clinical cohort? With more specific sub-questions: -are variations in the alpha-adducin gene (ADD1) associated with the risk of the outcome-measures under study? -are genetic polymorphisms that play a role in metabolism of homocysteine (an established risk factor for atherosclerosis and stroke) associated with the risk of the outcome-measures under study? -are other genetic variations that influence risk factors for atherosclerosis associated with the risk of the outcome-measures under study? 3) Can results from a genome-wide association study, aimed at identifying new risk genes for TIA or stroke, be replicated in this clinical cohort?	—

Measure

Time frame

The study is primarily aimed at the collection and storage of blood samples and questionnaire data for future scientific research. The exact content of this study is at this moment only partially specified. We aim to answer the following research questions: 1) Are (genetic) factors that play a role in blood coagulation (hemostasis) associated with the risk of TIA or stroke in this clinical cohort? With more specific sub-questions: -are levels of fibrinogen and fibrinogen-degradation products associated with the risk of the outcome-measures under study? - are variations in the fibrinogen-FGA en FGG genes associated with the risk of the outcome-measures under study? -are other genetic variations that play a role in hemostasis associated with the risk of the outcome-measures under study? 2) Are new genetic risk factors for atherosclerosis associated with the risk of TIA or stroke in this clinical cohort? With more specific sub-questions: -are variations in the alpha-adducin gene (ADD1) associated with the risk of the outcome-measures under study? -are genetic polymorphisms that play a role in metabolism of homocysteine (an established risk factor for atherosclerosis and stroke) associated with the risk of the outcome-measures under study? -are other genetic variations that influence risk factors for atherosclerosis associated with the risk of the outcome-measures under study? 3) Can results from a genome-wide association study, aimed at identifying new risk genes for TIA or stroke, be replicated in this clinical cohort?

—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results